Eurofins Transplant Genomics Announces 2021-2022 Scientific Advisory Board prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Published: Jun 04, 2021
Transplant physicians to present 40 scientific abstracts, plus two symposia to highlight latest data from multi-center studies on clinical utility of AlloSure
SOUTH SAN FRANCISCO, Calif., June 04, 2021 (GLOBE NEWSWIRE)
CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced its participation in the 2021 American Transplant Congress (ATC), including two symposia and the presentation of 40 scientific abstracts.
“We look forward to sharing groundbreaking findings from ADMIRAL and KOAR, both multi-center, prospective studies as we continue to drive innovation in transplantation,” said Reg Seeto, President & CEO of CareDx. “These are the first long-term studies on donor-derived cell-free DNA. They are part of 40 scientific abstracts from more than 30 authors, re
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
CareDx Transplant Leadership Showcased at ASTS 2021
CareDx, Inc.January 8, 2021 GMT
SOUTH SAN FRANCISCO, Calif., Jan. 08, 2021 (GLOBE NEWSWIRE) CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, announced it will be showcasing new transplant data at the upcoming 21st Annual American Society of Transplant Surgeons (ASTS) Digital Winter Symposium.
CareDx is sponsoring two symposia with key clinical leaders within transplantation, the speakers covering their real-world experiences using AlloSure to optimize care for their transplant patients, and highlighting novel data on the clinical utility of AlloSure. Of note, Dr. Jason Wellen will share initial data from the ADMIRAL study on AlloSure surveillance outcome